CINCINNATI--(BUSINESS WIRE)--Aerpio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases, today announced the publication of preclinical data demonstrating that lead candidate, AKB-9778, reduces abnormal blood vessel growth and leakage in mouse models of ophthalmic diseases, such as diabetic macular edema (DME) and age-related macular degeneration. These data were published in collaboration with researchers at Johns Hopkins School of Medicine, Max Planck Institute, and Duke University in the September 2, 2014, issue of The Journal of Clinical Investigation. AKB-9778 is a small molecule activator of Tie2 currently in a Phase 2 clinical study for the treatment of DME.
Help employers find you! Check out all the jobs and post your resume.
